- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02230683
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension (PH)
October 28, 2016 updated by: Conatus Pharmaceuticals Inc.
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
This is an open-label pilot study to evaluate the safety, tolerability, and efficacy of IDN-6556 in treating portal hypertension in subjects with liver cirrhosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Studies in patients with liver disease have demonstrated that cCK18 is elevated in the serum of patients and has been associated with disease severity.
Studies have also shown that cCK18 is generally elevated to a higher degree in cirrhosis than in other liver diseases.
In addition, increasing stages of cirrhosis from Child-Pugh A, Child-Pugh B to Child-Pugh C are associated with progressively higher levels of caspase cleaved cytokeratin 18.
This suggests that apoptosis and caspase activity are associated with the severity of disease.
IDN-6556 and its ability to inhibit inflammation and apoptosis may have a beneficial impact on both the dynamic and structural components associated with the pathogenesis of portal hypertension in cirrhosis.
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
West Haven, Connecticut, United States, 06516
- VA Connecticut Healthcare System
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20016
- Johns Hopkins Sibley Memorial Hospital
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
New Jersey
-
Newark, New Jersey, United States, 07103
- Rutgers New Jersey Medical School
-
-
New York
-
Manhasset, New York, United States, 11030
- North Shore University Hospital
-
NYC, New York, United States, 10016
- New York University Lagone Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19141
- Albert Einstein Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas Health Science Center at Houston
-
Houston, Texas, United States, 77030
- St. Luke's Health Baylor College of Medicine
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah Hospital
-
-
Virginia
-
Newport News, Virginia, United States, 23602
- Bon Secours Mary Immaculate Hospital
-
Richmond, Virginia, United States, 23249
- McGuire DVAMC
-
Richmond, Virginia, United States, 23226
- Bon Secours St. Mary's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and able to understand and willing to comply with the requirements of the study
- Clinical, radiological, or biochemical evidence of liver cirrhosis
Evidence of portal hypertension as evidenced by any of the following:
- Splenomegaly, on imaging and/or clinical evaluation, with platelet count of <120,000 at study entry, or
- Presence of small sized varices on screening endoscopy and/or collateral circulation on imaging, or
- Presence of medium/large varices that have never bled and have been obliterated with endoscopic ligation
- Portal hypertension defined as a hepatic venous pressure gradient (HVPG) >5 mmHg at Screening
- Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from Screening to one month after the last dose of study drug.
Exclusion Criteria:
- Decompensated cirrhosis as defined by the presence of overt ascites (requiring diuretics), overt encephalopathy (requiring specific therapy), or history of variceal hemorrhage.
- Known infection with HIV
- Hepatic failure defined as total bilirubin ≥12 mg/dL
Other non-liver organ failure, including:
- Renal failure defined as creatinine ≥ 2.0 mg/dL
- Cerebral failure defined as hepatic encephalopathy grade III or IV
- Coagulation failure defined as INR ≥ 2.5 or platelets ≤ 20x109/L
- Hemodynamic requirement for inotropic support
- Child-Pugh score of 10-15 (Child-Pugh C classification)
Use of vasoactive drugs (at or within 3 months of Screening) that may impair hepatic blood flow; examples include but are not limited to:
- β-blockers, including carvedilol
- Nitrates
- Vasopressin (or analogues)
- Phosphodiesterase inhibitors (prescribed daily for pulmonary hypertension; p.r.n. use for erectile dysfunction is permitted)
Change in dose or regimen within 3 months of Screening of:
- Fibrates or statins
- Angiotensin II receptor antagonist or angiotensin converting enzyme (ACE) inhibitor
Use of the following drugs within 2 months of Screening:
- Systemic corticosteroids
- Pentoxifylline
- Known or suspected use of illicit drugs or drugs of abuse (allowed if medically prescribed or indicated)
- Concomitant pancreatitis
- Evidence of portal vein thrombosis on Doppler ultrasound of the portal vasculature
- Active inflammatory bowel disease
- Diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA)
- Autoimmune hepatitis
- Hepatitis C Virus (HCV) infected subjects receiving or planning on receiving anti-viral therapy during the course of the study
- Hepatitis B Virus (HBV) infected subjects who have been on stable anti-HBV therapy for less than 3 months
- Hepatocellular carcinoma (HCC) at entry into the study
- Active non-liver malignancies other than curatively treated skin cancer (basal cell or squamous cell carcinomas)
- History or presence of clinically concerning cardiac arrhythmias, or prolongation of screening (pre-treatment) QT or QTc interval of >480 milliseconds (msec)
- Significant systemic or major illness other than liver disease, including coronary artery disease, cerebrovascular disease, pulmonary disease, renal failure, serious psychiatric disease, that, in the opinion of the Investigator would preclude the subject from participating in and completing the study
- Any subject that has received any investigational drug or device within 30 days of dosing or who is scheduled to receive another investigational drug or device in the course of the study
- If female, known pregnancy, or has a positive urine or serum pregnancy test, or lactating/breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IDN-6556 - Overall population
Overall evaluable population treated with IDN-6556 25 mg twice daily
|
25 mg BID
Other Names:
|
Experimental: IDN-6556 - Subgroup with Baseline HVPG < 12 mmHg
Subgroup for patients with Baseline HVPG < 12 mmHg that have been treated with IDN-6556 25 mg twice daily
|
25 mg BID
Other Names:
|
Experimental: IDN-6556 - Subgroup Baseline HVPG ≥ 12 mmHg
Subgroup for patients with Baseline HVPG ≥ 12 mmHg that have been treated with IDN-6556 25 mg twice daily
|
25 mg BID
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hepatic Venous Pressure Gradient (HVPG)
Time Frame: Baseline to Day 28/EOT (end of treatment)
|
Mean change of HVPG [mmHg] from Baseline to Day 28/EOT (end of treatment) for IDN-6556
|
Baseline to Day 28/EOT (end of treatment)
|
cCK18/M30
Time Frame: Change from Baseline to Day 28/EOT
|
Absolute Mean Change of caspase-cleaved cytokeratin serum levels (cCK18/M30); the statistical analysis is based on the mean change in log-transformed cCK18/M30 from Baseline to Day 28/EOT (end of treatment) for IDN-6556
|
Change from Baseline to Day 28/EOT
|
Change in cCK18/M30
Time Frame: Baseline to Day 28/EOT (end of treatment)
|
Median change of caspase-cleaved cytokeratin serum levels (cCK18/M30) from Baseline to Day 28/EOT (end of treatment) for IDN-6556
|
Baseline to Day 28/EOT (end of treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Alanine Aminotransferase (ALT)
Time Frame: Baseline to 28 days/EOT
|
Median change of ALT from Baseline to Day 28/EOT (end of treatment) for IDN-6556
|
Baseline to 28 days/EOT
|
Change in Aspartate Aminotransferase (AST)
Time Frame: Baseline to 28 days/EOT
|
Median change of AST from Baseline to Day 28/EOT (end of treatment) for IDN-6556
|
Baseline to 28 days/EOT
|
Concentration of Caspase 3/7 RLU
Time Frame: Baseline to 28 days/EOT
|
Median change of concentration of Caspase 3/7 Relative Light Units from Baseline to Day 28/EOT (end of treatment) for IDN-6556
|
Baseline to 28 days/EOT
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: David Hagerty, MD, Conatus Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2014
Primary Completion (Actual)
May 1, 2015
Study Completion (Actual)
June 1, 2015
Study Registration Dates
First Submitted
August 28, 2014
First Submitted That Met QC Criteria
August 28, 2014
First Posted (Estimate)
September 3, 2014
Study Record Updates
Last Update Posted (Estimate)
December 21, 2016
Last Update Submitted That Met QC Criteria
October 28, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IDN-6556-11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingFibrosis, Liver | Cirrhosis, LiverChina
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
Clinical Trials on IDN-6556
-
University of AlbertaConatus Pharmaceuticals Inc.Completed
-
Conatus Pharmaceuticals Inc.Idun PharmaceuticalsCompleted
-
Conatus Pharmaceuticals Inc.CompletedLiver Diseases | Digestive System Diseases | Hepatic ImpairmentUnited States
-
Conatus Pharmaceuticals Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA)TerminatedAlcoholic HepatitisUnited States
-
Conatus Pharmaceuticals Inc.CompletedKidney Diseases | Renal Insufficiency | Renal Impairment | Kidney DiseaseUnited States
-
Conatus Pharmaceuticals Inc.CompletedLiver Diseases | Fibrosis | Non-alcoholic SteatohepatitisUnited States, Spain, Germany
-
Conatus Pharmaceuticals Inc.Idun PharmaceuticalsCompletedLiver Transplantation | Hepatitis | Carcinoma, Hepatocellular | CholestasisUnited States, Germany
-
Conatus Pharmaceuticals Inc.TerminatedLiver Cirrhosis | Acute on Chronic Hepatic Failure | Acute Liver Failure | Acute Alcoholic HepatitisUnited States, United Kingdom
-
Conatus Pharmaceuticals Inc.CompletedLiver Cirrhosis | Hepatic CirrhosisUnited States
-
Conatus Pharmaceuticals Inc.CompletedLiver Cirrhosis | Hepatic Fibrosis | Liver Fibrosis | Hepatic CirrhosisUnited States